In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Roche to create companion test for Clovis’ CO1686

Executive Summary

On the same day it received rights to a solid tumor compound from Pfizer Inc., Clovis Oncology Inc. (in-licenses cancer candidates) and Roche Molecular Diagnostics (a division of Roche’s Roche Diagnostics that operates in the US as Roche Molecular Systems Inc.) agreed to develop a companion diagnostic for the biotech’s CO1686 (AVL301), in preclinical studies for advanced non-small cell lung cancer.
Deal Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • R&D and Marketing (Licensing)

Related Companies